Literature DB >> 19149549

The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies.

Kristina Abel1.   

Abstract

Worldwide, the AIDS pandemic continues almost relentlessly. Women are now representing the fastest growing group of newly infected HIV-1 infected patients. The risk of mother-to-child-transmission (MTCT) of HIV-1 increases proportionally as many of these women are of childbearing age. The screening of pregnant women, the early diagnosis of HIV-1 infection, and the administration of antiretroviral therapy (ART) have helped to reduce MTCT significantly. However, this holds true only for developed countries. In many resource-poor countries, access to ART is limited, and breastfeeding, a major route of HIV-1 transmission, is essential to protect the infant from other infectious diseases preponderant in those geographic regions. HIV-1 infected children, in contrast to adult patients, have higher levels of virus replication that decline only slowly, and a subset progresses to AIDS within the first two years. Thus, it is imperative to understand pediatric HIV-1 pathogenesis to design effective prevention strategies and/or a successful pediatric HIV-1 vaccine. The review summarizes how MTCT of HIV-1 in humans can be modeled in the infant macaque model of SIV infection. Importantly, the infant macaque model of SIV infection provides the opportunity to study early virus-host interactions in multiple anatomic compartments. Furthermore, the review underlines the importance of evaluating SIV/HIV immune responses in the context of the normal developmental changes the immune system undergoes in the newborn. Thus, the pediatric SIV infection model provides a unique resource for preclinical studies of novel intervention therapies and vaccine strategies to stop MTCT of HIV-1.

Entities:  

Mesh:

Year:  2009        PMID: 19149549      PMCID: PMC2745952          DOI: 10.2174/157016209787048528

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  130 in total

Review 1.  Reflections on CD8 T-cell activation and memory.

Authors:  David Masopust; Rafi Ahmed
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance.

Authors:  K Van Herck; E Leuridan; P Van Damme
Journal:  Sex Transm Infect       Date:  2007-10       Impact factor: 3.519

Review 3.  Neonatal microbial flora and disease outcome.

Authors:  Milo F Vassallo; W Allan Walker
Journal:  Nestle Nutr Workshop Ser Pediatr Program       Date:  2008

4.  The immune privilege of the oral mucosa.

Authors:  Natalija Novak; Jörg Haberstok; Thomas Bieber; Jean-Pierre Allam
Journal:  Trends Mol Med       Date:  2008-04-07       Impact factor: 11.951

5.  Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

Authors:  Koen K A Van Rompay; Kristina Abel; Jonathan R Lawson; Raman P Singh; Kimberli A Schmidt; Thomas Evans; Patricia Earl; Danielle Harvey; Genoveffa Franchini; James Tartaglia; David Montefiori; Shilpa Hattangadi; Bernard Moss; Marta L Marthas
Journal:  J Acquir Immune Defic Syndr       Date:  2005-02-01       Impact factor: 3.731

6.  Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques.

Authors:  Yoshiaki Nishimura; Charles R Brown; Joseph J Mattapallil; Tatsuhiko Igarashi; Alicia Buckler-White; Bernard A P Lafont; Vanessa M Hirsch; Mario Roederer; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

7.  Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

Authors:  N L Haigwood; A Watson; W F Sutton; J McClure; A Lewis; J Ranchalis; B Travis; G Voss; N L Letvin; S L Hu; V M Hirsch; P R Johnson
Journal:  Immunol Lett       Date:  1996-06       Impact factor: 3.685

8.  HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.

Authors:  S L Rowland-Jones; D F Nixon; M C Aldhous; F Gotch; K Ariyoshi; N Hallam; J S Kroll; K Froebel; A McMichael
Journal:  Lancet       Date:  1993-04-03       Impact factor: 79.321

9.  HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission.

Authors:  Dara A Lehman; Michael H Chung; Grace C John-Stewart; Barbra A Richardson; James Kiarie; John Kinuthia; Julie Overbaugh
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

10.  Simian immunodeficiency virus of African green monkeys is apathogenic in the newborn natural host.

Authors:  B Beer; J Denner; C R Brown; S Norley; J zur Megede; C Coulibaly; R Plesker; S Holzammer; M Baier; V M Hirsch; R Kurth
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-07-01
View more
  26 in total

1.  Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.

Authors:  Jinyan Liu; Hualin Li; M Justin Iampietro; Dan H Barouch
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Facial musculature in the rhesus macaque (Macaca mulatta): evolutionary and functional contexts with comparisons to chimpanzees and humans.

Authors:  Anne M Burrows; Bridget M Waller; Lisa A Parr
Journal:  J Anat       Date:  2009-06-26       Impact factor: 2.610

3.  A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.

Authors:  Philippe Denoël; Mario T Philipp; Lara Doyle; Dale Martin; Georges Carletti; Jan T Poolman
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

4.  Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.

Authors:  Marta L Marthas; Koen K A Van Rompay; Zachary Abbott; Patricia Earl; Linda Buonocore-Buzzelli; Bernard Moss; Nina F Rose; John K Rose; Pamela A Kozlowski; Kristina Abel
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

Review 5.  Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?

Authors:  Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke
Journal:  ACS Chem Neurosci       Date:  2015-06-19       Impact factor: 4.418

6.  Myeloid-lymphoid ontogeny in the rhesus monkey (Macaca mulatta).

Authors:  Cynthia A Batchelder; Nadire Duru; Charles I Lee; Chris A R Baker; Louise Swainson; Joseph M Mccune; Alice F Tarantal
Journal:  Anat Rec (Hoboken)       Date:  2014-05-28       Impact factor: 2.064

7.  Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

Authors:  Koen K A Van Rompay; Kristina Abel; Patricia Earl; Pamela A Kozlowski; Juliet Easlick; Joseph Moore; Linda Buonocore-Buzzelli; Kimberli A Schmidt; Robert L Wilson; Ian Simon; Bernard Moss; Nina Rose; John Rose; Marta L Marthas
Journal:  Vaccine       Date:  2009-12-06       Impact factor: 3.641

Review 8.  Nonhuman primate models of human viral infections.

Authors:  Jacob D Estes; Scott W Wong; Jason M Brenchley
Journal:  Nat Rev Immunol       Date:  2018-06       Impact factor: 53.106

Review 9.  Immunology of pediatric HIV infection.

Authors:  Nicole H Tobin; Grace M Aldrovandi
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.